MOSCOW (MRC) -- Essen-based Evonik Industries, a leading specialty chemicals manufacturer has recently reduced production capacity for superabsorbents by 40,000 metric tons to 530,000 meric tons per year. The production lines concerned are those at the Garyville and Greensboro (North Carolina, USA) sites, two of Evonik’s five superabsorbents production sites worldwide, said the producer in its press release.
"With this measure we’re adapting to demand trends. We plan to take the opportunity to bring capacity to the technological state of the art and to start up the lines again in 1-2 years," says Norbert Westerholt, head of the Baby Care Business Line at Evonik.
Evonik is pursuing the goal of remaining a reliable, competitive, and innovative partner of superabsorbents customers over the long term.
As one of the leading suppliers of superabsorbents, Evonik is established as a reliable, innovative and long-term partner in the superabsorbents industry.
As MRC informed before, in 2015, Evonik Industries invested over EUR400 mln in its plants in Germany in 2015. Last year, Evonik once again demonstrated its considerable power to create at its German sites. Thus, according to a recent projection, the company invested more than EUR 400 million in its domestic production plants. The lion’s share of the funds (around two-thirds) was divided among Evonik’s five-largest sites in Germany: Marl (hundreds of millions of euros), Hanau, Essen, Darmstadt, and Wesseling (tens of millions of euros at each site).
Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world. In fiscal 2015 more than 33,500 employees generated sales of around EUR13.5 billion and an operating profit (adjusted EBITDA) of about EUR2.47 billion.
MRC